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ered as ‘orphan’. All the 58 orphan strains were analysed using 24
loci MIRU-VNTR and appropriate genotypes were identiﬁed. Over-
all using both techniques, CAS familywas predominant, comprising
of 253(40.3%) isolates, followed by EAI in 172(27.4%), Beijing in
110(17.5%), Manu in 41(6.5%), T in 31(4.9%), H in 11(1.8%), X in 4
(0.6%), Africanum in 4(0.6%) andUral in one. Using theHuntereGas-
ton diversity index (HGI), the allelic diversity of the loci MIRU10,
MIRU 16, MIRU 23, MIRU27, MIRU31, Mtub04, Mtub21, Mtub30,
QUB11b, QUB26 and QUB4156 were highly discriminant.
Conclusion: CAS was most predominant in Northern and west-
ernpartsof Indiaviz:Agra,Delhi, Punjab,Mumbai andNagpurwhile
EAIwaspredominant in Chennai, Hyderabad.Highest prevalence of
Beijing was found in Assam and Kolkata. Our data clearly demarks
theprevalenceof speciﬁcM. tuberculosisgenotypesamongdifferent
geographical regions.
The authors like to thank Dr. Rajpal Singh, Dr. HF Daginawala,
Dr. Bandana Choudhury and Dr. Uma Devi for providing the MTB
isolates.
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Background: The present measure of the success of TB
treatment is fraught with problems. A cytokine biomarker(s), a
qualitative and quantitative reﬂection of the treatment success,
is thus warranted. Because TB treatment is expected to affect
macrophage and mycobacteria interactions and, consequently
cytokine(s) elaboration, a biomarker(s) seems crucial to assess its
success.
Methods & Materials: We studied the effect of anti-TB drugs
isoniazid (INH), rifampicin (RIF), streptomycin (STP) and ethambu-
tol (EMB) on IL-1, IL-6, IL-10, IL-12 p40 and IL-12 p70 elaboration
by mouse peritoneal macrophages (PMs) infected with M. tuber-
culosis H37Rv for 6 h, 24 h, 4 days and 7 days, in vitro, by using a
multiplex suspension cytokine array system.
Results: INH, at 6 h, at 0.4g/ml (MIC: 0.2g/ml) and not at 0.1
and 0.2 g/ml, and at 24 h and on D 4 and D 7, at all the tested
concentrations, signiﬁcantly (p <0.001) suppressed IL-6 elabora-
tion. RIF, at 6 h, lacked any effect on IL-6 elaboration at 0.4 g/ml
(MIC: 0.8g/ml), whereas at 0.8 and 1.6g/ml, and at all the tested
concentrations at 24 h and on D 4 and D 7, signiﬁcantly (p <0.001)
inhibited IL-6 elaboration. STP, at all the time-points, at 2.5 g/ml
(MIC: 5 g/ml), lacked any effect on IL-6 elaboration; however, at
5 and 10 g/ml it caused signiﬁcant (p <0.001) inhibition. Surpris-
ingly, EMB at 4, 8 and 16 g/ml (MIC: 8 g/ml) suppressed IL-6
elaboration at all the time-points studied. M. tuberculosis-infected
untreated controls, in contrast to the uninfected ones, irrespective
of the time-points, elaborated signiﬁcantly (p <0.001) high con-
centrations of IL-6 (infected controls, 365±30.41–777.5±74.45
pg/ml; uninfected controls, 15.25±1.77–21±1.41 pg/ml) only.
Curiously, all the other cytokines (IL-1, IL-10, IL-12 p40 and IL-12
p70) were unaffected by the drug treatments.
Conclusion: M. tuberculosis -infected PMs, in vitro, elaborated
IL-6 as the only major cytokine, which was signiﬁcantly inhibited
by anti-TB drugs. Therefore, IL-6 can be developed as a potential
biomarker or biosignature to assess the success of the treatment of
TB.
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Background: Globally, human tuberculosis (TB), continues to
be one of the deadliest public health problem, despite some recent
ground success. According to Global TB Report 2014 World over,
TB is showing a gradual declining trend, and during the period
2000 to 2013, an estimated 37 million lives were saved largely
due to improvements in its diagnosis and treatment. Nevertheless,
because deaths due to TB are considered preventable, it is only nec-
essary that work must continue to further improve on both these
fronts. TB is a chronic inﬂammatory disease caused by the faculta-
tive intra-macrophage pathogen Mycobacterium tuberculosis, and
their resultant interaction is known to elaborate a wide array of
cytokines (stand-alone as biomarkers, and as a group, as biosig-
natures), which, in turn, are believed to be the reﬂection of the
diseases progression and its status at a particular point in time.
Methods & Materials: We, thus studied the serum levels of
interleukin-2 (IL-2), IL-4, IL-6, IL-8, IL-10, tumor necrosis factor-
 (TNF-), GM-CSF and interferon- (IFN-) in TB patients, at Day
0, after one month, and after six month, by using a multiplex (Bio-
plex) suspension cytokine array. The standard curves for all the
cytokines were generated as per the protocol of the supplier.
Results: Results showed that after six month, only IL-2, IL-4, IL-
6, IL-8, TNF-, GM-CSF and IFN- showed a major increase; IL-10
showed the least increase only in a fewpatients. On the other hand,
IL-6, IL-8 and GM-CSF showed amaximum increase (IL-6, 140-fold;
IL-8, 180-fold;GM-CSF, 140-fold). The remaining cytokines showed
relatively lesser increase (IL-4, 1.1-fold; IL-10, 5-fold; IFN-, 80-fold
and TNF-, 65-fold).
Conclusion:We conclude that as stand-alone IL-6, IL-8 andGM-
CSF may function as potential biomarkers or together, as a group,
may be considered as a biosignature for the diagnosis of TB.
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